Galaxy Surfactants Limited — PPTs, 16-05-2025: Investor Presentation

1. Financial Highlights:

Galaxy Surfactants posted consolidated revenue of ₹4,249.5 Cr for the year, up 11% YoY. EBITDA increased 2.5% to ₹510 Cr, with stable per-tonne EBITDA around ₹19,868. Q4 revenue jumped 21% YoY to ₹1,045.7 Cr, while EBITDA grew 7.3% to ₹134.7 Cr. PAT rose 1.1% to ₹305 Cr for the year but dipped 2.1% in Q4 to ₹77.5 Cr. India and AMET volumes were flat; Rest of World volumes saw strong double-digit growth. The balance sheet remains healthy with ₹3,462 Cr assets and low net debt (Debt/Equity ~0.1). Operating cash flow was robust at ₹420.5 Cr.

2. Strategic Initiatives & Growth Drivers:

Heavy R&D focus with 111 patents granted and 32 pending supports innovation-led growth. Capacity expansions at Indian (Tarapur, Jhagadia, Taloja), Egyptian, and US facilities aim to boost global reach. Emphasis on higher-margin specialty care and performance surfactants aligns with deepening customer relationships. Sustainability and ESG initiatives remain integral to operations.

3. Business Developments:

Global presence strengthened via subsidiaries Tri-K Industries (US) and Galaxy Chemicals (Egypt), enhancing manufacturing and R&D. New product development continues through a “Consumer to Chemistry” innovation approach with active client collaboration. No recent acquisitions; specialty grade portfolio expansion ongoing.

4. Market Position & Competitive Advantage:

India’s largest oleochemical surfactants maker and a preferred global supplier to 1,500+ FMCG clients across 80+ countries. Vertical integration and strong R&D create high barriers to entry. Long-term MNC client relationships provide revenue stability. Focus on quality, innovation, and sustainability fortifies competitive moats.

5. Investor Implications:

Solid volume growth amid raw material inflation and stable margins suggest positive growth potential. Healthy balance sheet and strong cash flows underpin further capex and innovation. Investors should watch execution on specialty care expansion, global volume momentum, and raw material cost management.